Biogen may sue third generic drug maker to protect MS drug Tecfidera
Intellectual Property 2021-12-10 4:14 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au